Impact of simultaneous assay, the PCNA, cyclinD1, and DNA content with specimens before and after preoperative radiotherapy on prognosis of esophageal cancer-possible incorporation into clinical TNM staging system

Table 1 Relation between accumulated survival rates and clinicopathological and tumor cell protein expression pre- or post-radiotherapy

Factors	Patient number	Median (mo)	Mean (mo)	3 yr (%)	5 yr (%)	10 yr (%)	Log-rank	P
Sex
Male	28	48	76	60.7	49.7	38.2
Female	19	27	62	44.9	45.1	38.1	0.6705	0.2513
Age (yr)
50	26	31	66.6	50.4	49.7	36.8
> 50	21	50	74.2	57.7	45.2	39.6	0.2317	0.4084
Total dose
35 Gy	23	53	78.4	56.5	56.5	46.3
> 35 Gy	24	35.5	63.5	52.6	39.6	30.3	0.647	0.2588
Site of lesion
Upper-thoracic	10	69.5	81.5	70	70	46.7
Middle-thoracic	37	31	67.9	50.2	41.7	35.4	0.8864	0.1877
Tumor length
7.0 cm	39	48	77.1	58.1	50.1	41.4
> 7.0 cm	8	22.5	40	37.5	37.5	18.8	0.9653	0.1672
Pathological change
after radiation
Grade III	24	93	95	70.8	62.3	57.6
Grade II	15	26	49.3	40	40	16
Grade I	8	13	38.6	31.1	15.6	15.6	5.145	0.0764
T stage
T1	11	135	112.9	90.9	81.8	61.9
T2	19	48	77.5	57.9	46.9	41
T3	17	19	36.1	26	26	17.3	8.98	0.0113
N stage
N0	39	60	81.7	61.5	53.7	42.6
N1	8	12	17.6	16.7	16.7	0	2.417	0.0078
Pre-radiotherapy PCNA
Low expression	21	35.5	67.4	50	42	32.9
High expression	26	48	75.1	60.4	55.2	44.2	0.888	0.1873
Pre-radiotherapy cyclinD1
Negative	21	135	106.3	80.9	71.4	61.6
Positive	20	19	46.2	32.5	32.5	24.4
Strong positive	6	24	28.7	33.3	16.7	0	10.399	0.0055
Pre-radiotherapy
DNA content
I+II Type	10	98.5	88.9	60	60	50
III+IV Type	37	40	65.9	53	44.3	34.3	0.5158	0.3032
Post-radiotherapy PCNA
Low expression	17	135	107.4	81.5	73.9	61.8
High expression	30	18	21.4	16.1	9.8	0	4.1124	2E-05
Post-radiotherapy cyclinD1
Negative	17	77	94.1	76.5	70.4	49.8
Positive	22	30	64.4	53.1	43.1	37.8
Strongly positive	8	21	39	12.5	12.5	12.5	7.9215	0.0191
Pre-radiotherapy
DNA content
I+II Type	23	135	110.7	87	78.3	60.2
III+IV III+IV Type	24	20	32.5	22	16.6	16.6	3.7074	0.0001

Prognostic parameters in 47 patients with SCC of esophagus.